Rahal Ahmad, Musher Benjamin
Division of Hematology-Oncology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Department of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
J Surg Oncol. 2017 Jul;116(1):94-103. doi: 10.1002/jso.24626. Epub 2017 Apr 13.
Outcomes of pancreatic adenocarcinoma (PDA) remain dismal despite extensive clinical investigation. Combination chemotherapy provides modest improvements in survival above best supportive care, and immunotherapy has thus far not proven effective. Nevertheless, growing insight into antitumor immunity and the tumor microenvironment has inspired the discovery of novel agents targeting PDA. Oncolytic viruses represent an emerging class of immunotherapeutic agents that have undergone extensive preclinical investigation and warrant further investigation in well-designed clinical trials.
尽管进行了广泛的临床研究，胰腺腺癌（PDA）的预后仍然很差。联合化疗相比最佳支持治疗仅能适度提高生存率，而且免疫疗法迄今为止尚未证明有效。然而，对抗肿瘤免疫和肿瘤微环境的深入了解激发了针对PDA的新型药物的发现。溶瘤病毒是一类新兴的免疫治疗药物，已经过广泛的临床前研究，值得在精心设计的临床试验中进一步研究。
